Ivermectin doesn’t show meaningful reduction in COVID-19 – Axios

Ivermectin, a drug used to treat parasitic infections, has no meaningful benefit for treating COVID-19 symptoms, according to a new study from Duke University.

Why it matters: The Duke study is one of the largest clinical trials to show ivermectin which soared in popularity to treat COVID symptoms during the pandemic is not effective for doing so.

What they're saying: "Given these results, there does not appear to be a role for ivermectin outside of a clinical trial setting, especially considering other available options with proven reduction in hospitalizations and death," Adrian Hernandez, the executive director of the Duke Clinical Research Institute, said in a statement. Hernandez led the study.

The big picture: This was not the first study to suggest the ineffectiveness of ivermectin against COVID-19.

What's next: Duke plans to study ivermectin further, with another volunteer group receiving 50% more of the drug than it did in this study.

Go deeper: Read the full study here.

More here:

Ivermectin doesn't show meaningful reduction in COVID-19 - Axios